Advertisement

Presenting an Immunogenicity Risk Assessment to Regulatory Agencies

  • Paul Chamberlain
Part of the Biotechnology: Pharmaceutical Aspects book series (PHARMASP, volume VIII)

Keywords

Drug Product Therapeutic Protein Bioanalytical Method Monoclonal Antibody Product Pharmacodynamic Marker 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Baert, F., Noman, M., Vermeire, S., Van Assche, G., D’Haens, G., Carbonez, A., and Rutgeerts, P. 2003. Influence of immunogenicity on the long-term efficacy of infliximab in Crohn’s disease. N. Engl. J. Med. 348:601–608.PubMedCrossRefGoogle Scholar
  2. Benjamin, R., Cobbold, S., Clark, M. and Waldmann, H. 1986. Tolerance to rat monoclonal antibodies: implications for serotherapy. J. Exp. Med. 163:1539–1552.PubMedCrossRefGoogle Scholar
  3. Bennett, C.L., Luminari, S., Nissenson, A.R., Tallman, M.S., Klinge, S.A., McWilliams, N., McKoy, J.M., Kim, B., Lyons, E.A., Trifilio, S.M., Raisch, D.W., Evens, A.M., Kuzel, T.M., Schumock, G.T., Belknap, S.M., Locatelli, F., Rossert, J., and Casadevall, N. 2004. Pure Red-cell Aplasia and epoetin therapy. N. Engl. J. Med. 351:1403–1408.PubMedCrossRefGoogle Scholar
  4. Cheifetz, A., Smedle,y M., Martin, S., Reiter, M., Leone, G., Mayer, L., and Plevy, S. 2003. The incidence and management of infusion reactions to infliximab: a large center experience. Am. J. Gastroenterol. 98:1315–1324.PubMedCrossRefGoogle Scholar
  5. Cheifetz, A. and Mayer, L. 2005. Monoclonal antibodies, immunogenicity, and associated infusion reactions. Mnt. Sinai J. Med. 72:250–256.Google Scholar
  6. Chirino, A.J., Ary, M.L., and Marshall, S.A. 2004. Minimizing the immunogenicity of protein therapeutics. Drug Discov. Today 9:82–90.PubMedCrossRefGoogle Scholar
  7. EMEA. 2006a. The European Agency for the Evaluation of Medicinal Products (EMEA). Guideline on Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: non-clinical and clinical issues, EMEA/CHMP/BMWP/42832/2005 (http://www.emea.europa.eu/pdfs/human/biosimilar/4283205en.pdf)Google Scholar
  8. EMEA. 2006b. The European Agency for the Evaluation of Medicinal Products (EMEA). Guideline on Similar Medicinal Products containing recombinant erythropoietins, EMEA/CHMP/BMWP/94526/2005 (http://www.emea.eu.int/pdfs/human/biosimilar/9452605en.pdf).Google Scholar
  9. EMEA. 2007. The European Agency for the Evaluation of Medicinal Products (EMEA). Draft Guideline on immunogenicity assessment of biotechnology-derived therapeutic proteins, EMEA/CHMP/BMWP/14327/2006 (http://www.emea.europa.eu/pdfs/human/biosimilar/1432706en.pdf).Google Scholar
  10. FDA. 1997. US Department of Health and Human Services Food and Drug administration. Points to consider in the manufacture and testing of monoclonal antibody products for human use (http://www.fda.gov/Cber/gdlns/ptc_mab.pdf).Google Scholar
  11. FDA. 2002. US Department of Health and Human Services Food and Drug administration. Draft Guidance for Industry on Drugs, biologics, and medical devices derived from bioengineered plants for use in human and animals (http://www.fda.gov/cber/gdlns/bioplant.pdf).Google Scholar
  12. Ganson, N.J., Kelly, S.J., Scarlett, E., Sundy, J.S., and Hershfield, M.S. 2006. Control of hyperuricemia in subjects with refractory gout, and induction of antibody against poly(ethylene glycol) (PEG), in a phase i trial of subcutaneous PEGylated urate oxidase. Arthr. Res. & Ther. 8:R12 (http://www.arthritis-research.com/content/8/1/R12)CrossRefGoogle Scholar
  13. Gao, G., Lebherz, C., Weiner, D.J., Grant, R., Calcedo, R., McCullough, B., Bagg, A., Zheng, Y., and Wilson, J.M. 2004. Erythropoietin gene therapy leads to autoimmune anemia in macaques. Blood 103:3300–3302.PubMedCrossRefGoogle Scholar
  14. Gomord, V., Chamberlain, P., Jefferis, R., and Faye, L. 2005. Biopharmaceutical production in plants: problems, solutions and opportunities. Trends Biotechnol. 23:559–565.PubMedCrossRefGoogle Scholar
  15. Gupta, S., Indelicato, S.R., Jethwa, V., Kawabata, T., Kelley, M., Mire-Sluis, A.R., Richards, S.M., Rup, B., Shores, E., Swanson, S.J., and Wakshull, E. 2007. Recommendations for the design, optimization, and qualification of cell-based assays used for detection of neutralizing antibody responses elicited to biological therapeutics. J. Immunol. Method. 321:1–18CrossRefGoogle Scholar
  16. Hermeling, S., Crommelin, D.J., Schellekens, H., and Jiskoot, W. 2004. Structure-immunogenicity relationships of therapeutic proteins. Pharm. Res. 21:897–903.PubMedCrossRefGoogle Scholar
  17. Hermeling, S., Jiskoot, W., Crommelin, D., Bornaes, C., and Schellekens, H. 2005. Development of a transgenic mouse model immune tolerant for human interferon beta. Pharm. Res. 22:847–851.PubMedCrossRefGoogle Scholar
  18. ICH. 1995. International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline S6 on Preclinical safety evaluation of biotechnology-derived pharmaceuticals, CPMP/ICH/302/95 (http://www.emea.europa.eu/pdfs/human/ich/030295en.pdf).Google Scholar
  19. ICH. 2005. International conference on harmonisation (ICH) of technical requirements for registration of pharmaceuticals for human use. ICH harmonised tripartite guideline Q5E on Comparability of Biotechnological/Biological products subject to changes in their manufacturing process, CPMP/ICH/5721/03 (http://www.emea.europa.eu/pdfs/human/ich/572103en.pdf).Google Scholar
  20. Jaber, A. and Baker, M. 2007. Assessment of the immunogenicity of different interferon beta-1a formulations using ex vivo T-cell assays. J. Pharm. Biomed. Anal. 43:1256–1261.PubMedCrossRefGoogle Scholar
  21. Koren, E., Zuckerman, L.A., and Mire-Sluis, A.R. 2002. Immune responses to therapeutic proteins in humans – clinical significance, assessment and prediction. Curr. Pharm. Biotechnol. 3:349–360.CrossRefGoogle Scholar
  22. Kyewski, B. and Derbinski, J. 2004. Self-representation in the thymus: an extended view. Nat. Rev. Immunol. 4:688–698.PubMedCrossRefGoogle Scholar
  23. Mire-Sluis, A.R., Barrett, Y.C., Devanarayan, V., Koren, E., Liu, H., Maia, M., Parish, T., Scott, G., Shankar, G., Shores, E., Swanson, S.J., Taniguchi, G., Wierda, D., and Zuckerman, L.A. 2004. Recommendations for the design and optimization of immunoassays used in the detection of host antibodies against biotechnology products. J. Immunol. Method. 289:1–16.CrossRefGoogle Scholar
  24. Ottesen, J.L., Nilsson, P., Jami, J., Weilguny, D., Dühkkop, M., Bucchini, D., Havelund, S., and Fogh, J.M. 1994. The potential immunogenicity of human insulin and insulin analogues evaluated in a transgenic mouse model. Diabetologia 37:1178–1185.PubMedCrossRefGoogle Scholar
  25. Patten, P.A. and Schellekens, H. 2003. The immunogenicity of biopharmaceuticals. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 81–97. Dev. Biol. Basel, Karger, 112.Google Scholar
  26. Pendley, C., Schantz, A., and Wagner, C. 2003. Immunogenicity of therapeutic monoclonal antibodies. Curr. Opin. Mol. Ther. 5:172–179.PubMedGoogle Scholar
  27. Randolph, J.F., Stokol, T., Scarlett, J.M., and MacLeod, J.N. 1999. Comparison of biological activity and safety of recombinant canine erythropoietin with that of recombinant human erythropoietin in clinically normal dogs. Am. J. Vet. Res. 60:636–642.PubMedGoogle Scholar
  28. Roggen, E.L. 2006. Recent developments with B-cell epitope identification for predictive studies. J. Immunot. 3:137–149.CrossRefGoogle Scholar
  29. Rosenberg, A.S. 2003. Immunogenicity of Biological Therapeutics: a hierarchy of concerns. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 15–21. Dev. Biol. Basel, Karger, 112.Google Scholar
  30. Rosenberg, A.S. and Worobec, A. 2004a. A risk-based approach to immunogenicity of therapeutic protein products, Part 1: considering consequences of the immune response to a protein. BioPharm International, November 2004, 22–26 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=134110underline.Google Scholar
  31. Rosenberg, A.S. and Worobec, A. 2004b. A risk-based approach to immunogenicity of therapeutic protein products, Part 2: considering host-specific and product-specific factors impacting immunogenicity, BioPharm International, December 2004, 34–42 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=140695).Google Scholar
  32. Rosenberg, A.S. and Worobec, A. 2005. A risk-based approach to immunogenicity of therapeutic protein products, Part 3: effects of manufacturing changes in immunogenicity and the utility of animal immunogenicity studies. BioPharm International, January 2005, 32–36 (www.biopharminternational.com/biopharm/article/articleDetail.jsp?id=146216).Google Scholar
  33. Rosenberg, A.S. 2006. Effects of protein aggregates: an immunologic perspective. AAPS J. 8: Article 59, E501–E507 (http://www.aapsj.org/articles/aapsj080359/aapsj080359.pdf)Google Scholar
  34. Routledge, E., Falconer, M., Pope, H., Lloyd, I. and Waldmann, H. 1995. The effect of aglycosylation on the immunogenicity of a humanized therapeutic CD3 monoclonal antibody. Transplantation 60:847–853.Google Scholar
  35. Schellekens, H. 2002a. Bioequivalence and the immunogenicity of biopharmaceuticals. Nat. Rev. Drug Discov. 1:457–462.CrossRefGoogle Scholar
  36. Schellekens, H. 2002b. Immunogenicity of therapeutic proteins: clinical implications and future prospects. Clin. Ther. 24:1720–1740.CrossRefGoogle Scholar
  37. Shankar, G., Shores, E., Wagner, C. and Mire-Sluis, A. 2006. Scientific and regulatory considerations on the immunogenicity of biologics. Trends Biotechnol. 24:274–280.PubMedCrossRefGoogle Scholar
  38. Soos, J.M., Polsky, R.M., Keegan, S.P., Bugelski, P., and Herzyk D.J. 2003. Identification of natural antibodies to interleukin-18 in the sera of normal humans and three nonhuman primate species. Clin. Immunol. 109:188–196.PubMedCrossRefGoogle Scholar
  39. Strand, V., Kimberly, R., and Isaacs, J.D. 2007. Biologic therapies in rheumatology: lessons learned, future directions. Nat. Rev. Drug Discov. 6:75–92.PubMedCrossRefGoogle Scholar
  40. Tacey, R., Greway, A., Smiell, J., Power, D., Kromminga, A., Daha, M., Casadevall, N., and Kelley, M. 2003. The detection of anti-erythropoietin antibodies in human serum and plasma, Part I: validation of the protocol for a radioimmunoprecipitation assay. J. Immunol. Method. 283:317–329.CrossRefGoogle Scholar
  41. Tangri, S., Mothé, B.R., Eisenbraun, J., Sidney, J., Southwood, S., Briggs, K., Zinckgraf, J., Bilsel, P., Newman, M., Chesnut, R., Licalsi, C., and Sette, A. 2005. Rationally engineered therapeutic proteins with reduced immunogenicity. J. Immunol. 174:3187–3196.PubMedGoogle Scholar
  42. Thorpe, R. and Swanson, S.J. 2005. Current methods for detecting antibodies against erythropoietin and other recombinant proteins. Clin. Diag. Lab. Immunol. 12:28–39CrossRefGoogle Scholar
  43. Van der Meide, P.H. and Schellekens, H. 1997. Anti-cytokine autoantibodies: epiphenomenon or critical modulators of cytokine action. Biotherapy 10:39–48.PubMedCrossRefGoogle Scholar
  44. Van Walle, I., Gansemans, Y, Parren, P., Stas, P., and Lasters, I. 2007. Immunogenicity screening in protein drug development. Expert Opin. Biol. Ther. 7:405–418.Google Scholar
  45. Wagner, C.L., Schantz, A., Barnathan, E., Olson, A., Mascelli, M.A., Ford, J., Damaraju, L., Scaible, T., Maini, R.N., and Tcheng, J.E. 2003. Consequences of immunogenicity to the therapeutic monoclonal antibodies ReoPro® and Remicade®. In ‘Immunogenicity of Therapeutic Biological Products’, ed. Brown, F. and Mire-Sluis, A.R., pp. 37–53. Dev. Biol. Basel, Karger, 112.Google Scholar

Copyright information

© American Association of Pharmaceutical Scientists 2008

Authors and Affiliations

  • Paul Chamberlain

There are no affiliations available

Personalised recommendations